RxDoctor Payments Data

Edgar Kirby, MD

Urology · Wilmington, NCNPI 1326332024

Payments from drug & device makers

$14,182in general payments, 2019–2025

Across 638 payments — averaging $22.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$3K
  • Astellas Pharma US Inc$1K
  • Pfizer$969
  • Johnson & Johnson$908
  • Sumitomo Pharma America, Inc.$894
  • Coloplast$649
  • plus $7K from 44 others

What the payments were for

  • Food & beverage$13,26794%
  • Education$9156%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,182 in reported general payments places this provider in the 80th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$925,104
Medicare patients
927
Services billed
32,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide82$1,080,987
XiaflexCollagenase Clostridium Hist.15$192,447
NubeqaDarolutamide12$163,716
OrgovyxRelugolix36$91,584
GemtesaVibegron78$81,649
MyrbetriqMirabegron31$36,046
Abiraterone Acetate26$7,470
Tamsulosin Hcl462$7,324
Finasteride361$5,375
Testosterone Cypionate81$4,878
Testosterone25$4,195
Tadalafil38$4,064
Potassium Citrate ErPotassium Citrate27$2,557
Silodosin25$2,019
Solifenacin Succinate18$1,400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,216$1,117,033113 claims
Endo Pharmaceuticals Inc.Xiaflex$280$192,44715 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$894$173,233114 claims
BayerNubeqa$496$163,71612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 434 urology providers in North Carolina.

Other urology in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →